Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P48551
UPID:
INAR2_HUMAN
Alternative names:
Interferon alpha binding protein; Type I interferon receptor 2
Alternative UPACC:
P48551; A8KAJ4; D3DSE8; D3DSE9; Q15467; Q6FHD7
Background:
Interferon alpha/beta receptor 2 (IFNAR2) plays a pivotal role in the immune response against viral infections by forming a receptor complex with IFNAR1, essential for type I interferon signaling. This complex initiates the JAK-STAT signaling cascade, crucial for activating interferon-stimulated genes.
Therapeutic significance:
Linked to Immunodeficiency 45, IFNAR2's dysfunction highlights its critical role in antiviral immunity. Targeting IFNAR2 pathways could offer novel treatments for enhancing immune responses in related immunodeficiencies.